ALDR Gains As Pain Wanes, APRI Disappoints, PBYI's NDA Filing Delayed Yet Again

Shares of Alder BioPharmaceuticals Inc. (ALDR) rose more than 49% on Monday, following positive top-line data from two clinical trials evaluating ALD403 for migraine prevention.

from RTT - Biotech http://ift.tt/1UyxwvN
via IFTTT